NXPH4 and cervical squamous cell carcinoma: Tissue validation results have demonstrated a higher expression level of NXPH4 in cancers such as cervical squamous cell carcinoma, endocervical squamous cell carcinoma, cholangiocarcinoma, invasive breast cancer, colorectal adenocarcinoma, and oesophageal cancer [18].